ArticleJournal of nanobiotechnology2023
A novel Anti-ROS osteoblast-specific delivery system for ankylosing spondylitis treatment via suppression of both inflammation and pathological new bone formation.
Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Efficacy and safety of mind-body exercise for patients with axial spondyloarthritis: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2024Pooled it
- Responsive hydrogel delivery of DFO-programmed apoptotic bodies drives redox-immuno-angiogenic remodeling in diabetic wounds.Journal of nanobiotechnology · 2026Article
- Single-immunocyte transcriptomics reveal the role of natural killer cell-dependent exogenous antigen presentation in ankylosing spondylitis severity.Experimental & molecular medicine · 2026Article
- Piezo1-mediated autophagy promotes immune-inflammatory responses in ankylosing spondylitis.Cell death & disease · 2026Article
- Exploration of Multidimensional Treatment for Ankylosing Spondylitis: From Traditional Medications to Emerging Immune-Targeted Perspectives.International journal of general medicine · 2026Review
- Nanozymes for Bone Regeneration: Mechanistic Insights into Immune and Metabolic Microenvironment Modulation.International journal of nanomedicine · 2026Review
- Nanozymes in Therapeutic Prospects and Challenges for Autoimmune Diseases.International journal of nanomedicine · 2026Review
- Aptamers in Osteoimmune Regulation: Scientific Rationale, Emerging Evidence and Translational Challenges.International journal of nanomedicine · 2026Review
- Human peripheral osteoclast-precursor-development patterns reveal the significance of RPS17-dependent ribosome synthesis to Ankylosing Spondylitis lesions.Bone research · 2025Article
- Sprayable hydrogel sponge for neurovascular microenvironment reconstruction and inflammation modulation in diabetic wound healing.Bioactive materials · 2025Article
- Progress and challenges of functionalized bacterial encapsulation: A novel biotechnology for next-generation biotherapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Single-cell immunomics reveals the immunological hallmarks about the onset and different outcomes for ankylosing spondylitis patients.Clinical rheumatology · 2025Article
- Rethinking arthritis: exploring its types and emerging management strategies.Inflammopharmacology · 2025Review
- Serum Catestatin Levels and Its Relationship with Disease Activity in Patients with Ankylosing Spondylitis.Archives of rheumatology · 2025Article
- Aberrant bone formation and dysregulated bone homeostasis in ankylosing spondylitis.World journal of stem cells · 2025Article
- Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.Exploration (Beijing, China) · 2025Review
- Targeting Delivery of Dexamethasone to Inflamed Joints by Albumin-Binding Peptide Modified Liposomes for Rheumatoid Arthritis Therapy.International journal of nanomedicine · 2025Article
- Review
- [Advances in the Application of Nanozymes in Joint Disease Therapy].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Implications of siRNA Therapy in Bone Health: Silencing Communicates.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
Abstract
Ankylosing spondylitis (AS) is a common rheumatic disorder distinguished by chronic inflammation and heterotopic ossification at local entheses sites. Currently available medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs) and TNF inhibitors, are limited by side effects, high costs and unclear inhibitory effects on heterotopic ossification. Herein, we developed manganese ferrite nanoparticles modified by the aptamer CH6 (CH6-MF NPs) that can efficiently scavenge ROS and actively deliver siRNA into hMSCs and osteoblasts in vivo for effective AS treatment. CH6-MF NPs loaded with BMP2 siRNA (CH6-MF-Si NPs) effectively suppressed abnormal osteogenic differentiation under inflammatory conditions in vitro. During their circulation and passive accumulation in inflamed joints in the Zap70
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.